



November 29, 2023

## REMINDER: Limited Nirsevimab (Beyfortus™) Ordering Available for All VFC Providers

Dear VFC Provider,

If your practice sees young or vulnerable infants and have not yet ordered nirsevimab (Beyfortus™), order now to protect as many patients as possible with the scarce supplies available from the manufacturer. RSV season is here, with more than [11% of respiratory specimens in California testing positive for RSV during the week ending November 11<sup>th</sup>](#) and peak activity expected soon.

All VFC providers may order 50mg and 100 mg doses of Nirsevimab (Beyfortus™) in limited quantities, with approval dependent on a provider's history of ordering index routine infant vaccines (hepatitis B vaccine birth doses for hospitals, first doses of pneumococcal conjugate vaccine for all other providers).

As you order, please keep in mind:

- VFC orders may be approved for fewer doses than requested due to ongoing scarcity.
- Most providers who routinely give the index infant vaccines (listed above) will be approved for 5 doses per formulation; providers who see larger numbers of VFC patients may be eligible for larger orders. Requests from providers with minimal historical usage of the index vaccines may be denied.
- Providers who have previously requested and received nirsevimab may request additional doses. However, requests will be approved based on usage and on-hand inventory of nirsevimab, as well as available supply.
- Borrowing is not allowed. VFC doses must only be administered to VFC-eligible patients.
- Ensure doses administered are reported to CAIR, following the appropriate VFC Eligibility.
- Current limits and eligibility are subject to change.
- To facilitate rapid processing, please submit an order solely for nirsevimab.

The following resources can help your practice ensure prioritization of high-risk populations in light of limited nirsevimab supply.

- [IMM-1480 Nirsevimab \(Beyfortus\) Guide to Prevent Severe RSV in Infants and Toddlers \(eziz.org\)](#).
- [CDC Health Advisory \(10/23/23\): Limited Availability of Nirsevimab in the United States— Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus \(RSV\) during the 2023–2024 Respiratory Virus Season](#)

**Thank you and Happy Thanksgiving,**



California Department of Public Health | Immunization Branch  
Vaccines for Children (VFC) Program  
850 Marina Bay Parkway  
Richmond, CA 94804  
**Phone: 877-2GET-VFC (877-243-8832)**  
**Fax: 877-FAXX-VFC (877-329-9832)**  
**Email: [MyVFCVaccines@cdph.ca.gov](mailto:MyVFCVaccines@cdph.ca.gov)**

**EZIZ.org**